BAUSCH- Health EARNINGS 1 Q 2024 MAY 2, 2024 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to separat ...

Exhibit 99.1 CH-Health "We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan®, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb. • RED-C: prevention and delay of first episode of hepatic encephalopathy ◦ Enrollment of the second global Phase 3 trial completed in April 2024. Enrollment of both global Phase 3 studies are now complete and currently in ...

Bausch Health (BHC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power o ...

The shares of pharma stock Bausch Health Companies Inc (NYSE:BHC) have taken a tumble since their recent April 3 nearly two-year high of $11.46. Starting off this week on a sour note with a 6.9% loss -- BHC's worst daily percentage drop since September -- the stock is looking to extend its slide today, down 2.5% at $9.03 at last glance. For those curious about buying in on the dip, however, the recent pullback has BHC within one standard deviation of its 50-day moving average, a trendline with historically ...

Bausch Health (BHC) , along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it has filed a lawsuit against Amneal Pharmaceuticals (AMRX) and its subsidiaries.The lawsuit was filed on the heels of the Notice of Paragraph IV Certification, stating that Amneal submitted an abbreviated new drug application (ANDA) to the FDA seeking approval to market a generic version of Salix’s lead drug Xifaxan (rifaximin) 550 mg tablets.Xifaxan 550 mg tablets are indicated for the reduction in ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Zac ...

Bausch Health Companies Inc.'s (BHC) fourth-quarter results were better than expected. The company’s adjusted earnings per share of $1.15 beat the Zacks Consensus Estimate of $1.01. The reported figure also increased from $1.02 in the year-ago quarter.Total revenues of $2.41 billion were up 10% year over year. The top line beat the Zacks Consensus Estimate of $2.25 billion.Excluding the favorable impact of foreign exchange rates of $6 million and the impact of acquisitions worth $122 million, revenues incre ...

Bausch Health Companies Inc. (NYSE:BHC) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Senior Vice President, Chief Financial Officer (interim) Maria Likuris - Investor Relations Conference Call Participants Glen Santangelo - Jefferies Schuyler van den Broek - Piper Sandler James - Evercore ISI Chi - Bank of America Douglas Miehm - RBC Capital Markets Michael Nedelcovych - TD Cowen Operator Greetings. Welcome to the Ba ...

For the quarter ended December 2023, Bausch Health (BHC) reported revenue of $2.41 billion, up 9.8% over the same period last year. EPS came in at $1.15, compared to $1.02 in the year-ago quarter.The reported revenue represents a surprise of +7.15% over the Zacks Consensus Estimate of $2.25 billion. With the consensus EPS estimate being $1.01, the EPS surprise was +13.86%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...